目的:分析巴瑞替尼所致药物不良反应(adverse drug reactions,ADRs)的临床特点,为临床安全用药提供参考.方法:检索中国知网、万方、维普、Pubmed和Web of Science数据库(截至 2023 年 3 月),收集巴瑞替尼相关ADRs的病例报告文献,进行描述性统计分析.结果:收集到24 篇文献共25 例病例,其中男性12 例,女性 13 例;年龄 8～86 岁,平均年龄(54.48±17.61)岁.ADRs 大多发生在用药后 3 个月内(68.00%),以导致感染(病毒感染、真菌感染)和皮肤及其附件损害占比最高,其次为出血及凝血系统损害和肌肉骨骼损害.多数患者经停药、对症治疗后好转,1 例因原发疾病进展预后不良.结论:巴瑞替尼不良反应可累及多个系统/器官,使用时应加强监测,提高患者用药安全.
Literature analysis of adverse drug reactions induced by baricitinib
Objective:To analyze the clinical characteristics of adverse drug reactions(ADRs)induced by baricitinib.Methods:The databases of CNKI,Wanfang,VIP,Pubmed and Web of Science were searched up to March 2023,and the ADRs induced by baricitinib were collected and descriptively analyzed.Results:Totally 24 literatures were included,involving25 cases(12 males and 13 females),with an average age of 54.48±17.61(8～86)years.Most ADRs occurred within 3 months(68.00%).Infections(viral and fungal infections)and skin and its appendages damage accounted for the highest proportion,followed by bleeding and coagulation system damage and musculoskeletal damage.Most patients improved after discontinuation of medication and symptomatic treatment,and one case had a poor prognosis due to the progression of primary disease.Conclusion:The adverse reactions of baricitinib can affect multiple systems/organs,and monitoring should be strengthened to improve the safety of patients.
NETL
NSTL
万方数据
